1. Home
  2. AMCX vs FHTX Comparison

AMCX vs FHTX Comparison

Compare AMCX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

HOLD

Current Price

$7.70

Market Cap

331.2M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.63

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
FHTX
Founded
1980
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.2M
360.8M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
AMCX
FHTX
Price
$7.70
$5.63
Analyst Decision
Sell
Strong Buy
Analyst Count
5
7
Target Price
$6.50
$11.43
AVG Volume (30 Days)
360.5K
200.8K
Earning Date
02-11-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,316,303,000.00
$24,518,000.00
Revenue This Year
N/A
$40.91
Revenue Next Year
N/A
$11.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$2.95
52 Week High
$10.28
$6.95

Technical Indicators

Market Signals
Indicator
AMCX
FHTX
Relative Strength Index (RSI) 35.56 50.19
Support Level $7.69 $5.46
Resistance Level $8.11 $6.29
Average True Range (ATR) 0.27 0.39
MACD -0.01 -0.07
Stochastic Oscillator 16.98 14.08

Price Performance

Historical Comparison
AMCX
FHTX

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: